Company news

Paradigm Biopharmaceuticals Ltd. news in 2022

Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Phase 3 OA Trial to Proceed after Formal Safety Review

December 28, 2022

PAR Receives Allowance for Key US Patent

December 11, 2022

Paradigm CEO steps down & Appointment of MD

November 21, 2022

Paradigm Receives $7.4m R&D Tax Incentive Refund

November 18, 2022

Paradigm Doses First UK Participant in Phase 3 Trial

October 25, 2022

PAR Reports Successful Primary Endpoint in Phase 2 Trial

October 3, 2022

Successful MPSVI Safety Review and PARA OA 008 Update

September 25, 2022

Successful Completion of Entitlement Offer

September 12, 2022

2022 Annual Report and Appendix 4E

August 25, 2022

PAR Non-Renounceable Rights Issue Offer Booklet

August 21, 2022

Investor Presentation - $66m Capital Raise

August 14, 2022

Paradigm Launches $66M Capital Raising

August 14, 2022

Paradigm provides MPS Clinical Program update

August 7, 2022

Quarterly Update and Appendix 4C - quarterly

July 27, 2022

Paradigm Partners with NFL Alumni Health for OA Program

July 13, 2022

Paradigm reports global progress in phase 3 study

July 5, 2022

100% Recruitment in Synovial Fluid Biomarker Trial

June 30, 2022

Paradigm Reports Australian Patent Acceptance

June 29, 2022

Paradigm Receives $8.2m R&D Tax Incentive Refund

June 6, 2022

Paradigm Appoints Experienced US-Based CEO

May 29, 2022

Paradigm Doses First US Subjects under Phase 3 trial

April 28, 2022

FDA Grants Paradigm Fast Track Designation For OA

April 12, 2022

Clarification of recent analyst report on Patent Protection

March 9, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

Paradigm 1HY22 Key Activity Highlights

February 23, 2022

Paradigm treats first subjects in phase 3 trial of Zilosul

January 12, 2022

Decks in 2022